Introduction：Basic information about CAS 1351758-81-0|HG-10-102-01, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | HG-10-102-01 |
|---|
| CAS Number | 1351758-81-0 | Molecular Weight | 377.825 |
|---|
| Density | 1.4±0.1 g/cm3 | Boiling Point | 641.1±65.0 °C at 760 mmHg |
|---|
| Molecular Formula | C17H20ClN5O3 | Melting Point | / |
|---|
| MSDS | / | Flash Point | 341.5±34.3 °C |
|---|
Names
| Name | (4-(5-chloro-4-(methylamino)pyrimidin-2-ylamino)-3-methoxyphenyl)(morpholino)methanone |
|---|
| Synonym | More Synonyms |
|---|
HG-10-102-01 BiologicalActivity
| Description | HG-10-102-01 is a potent and selective inhibitor of wild-type LRRK2(IC50=23.3 nM) and the G2019S mutant(IC50=3.2 nM)IC50 Value: 23.3 nM (WT LRRK2); 3.2 nM (LRRK2 G2019S) [1]Target: LRRK2HG-10-102-01 maintains the ability to potently inhibit the biochemical activity of wild-type and G2019S mutant LRRK2. HG-10-102-01 exhibited biochemical IC50s of 20.3 and 3.2 nM against wild-type LRRK2 and LRRK2[G2019S], respectively. At a concentration of 10 μM, HG-10-102-01 only inhibited the kinase activities of MLK1 and MNK2 to greater than 80% of the DMSO control. Dose-response analysis revealed inhibition of MLK1 with an IC50 2.1 μM and MNK2 with an IC50 0.6 μM. KinomeScan analysis against a near comprehensive panel of 451 kinases at a concentration of 1 μM resulted in no interactions detected with kinases other than G2019S LRRK2 with the exception of one mutant form of c-Kit (L576P) demonstrating the outstanding selectivity of this inhibitor.HG-10-102-01 significantly inhibited phosphorylation of wildtype LRRK2 and LRRK2[G2019S] mutant at Ser910 and Ser935 at 0.3-1.0 μM in cell culture, which is approximately the same potency as LRRK2-IN-1 (1). HG-10-102-01 is relatively insensitive to the A2016T mutation which suggests that this mutant will not be useful to validate whether the pharmacological effects of the compound are LRRK2-dependent.HG-10-102-01 can inhibit phosphorylation of Ser910 and Ser935 of LRRK2 in brain and peripheral tissues following intraperitoneal doses of 50 mg/kg. Further optimization of this chemo-type especially in regards to in vivo half-life will be reported in due course [1]. |
|---|
| Related Catalog | Signaling Pathways >>Autophagy >>LRRK2Research Areas >>Neurological Disease |
|---|
| References | [1]. Choi HG, et al. Brain Penetrant LRRK2 Inhibitor. ACS Med Chem Lett. 2012 Aug 9;3(8):658-662. |
|---|
Chemical & Physical Properties
| Density | 1.4±0.1 g/cm3 |
|---|
| Boiling Point | 641.1±65.0 °C at 760 mmHg |
|---|
| Molecular Formula | C17H20ClN5O3 |
|---|
| Molecular Weight | 377.825 |
|---|
| Flash Point | 341.5±34.3 °C |
|---|
| Exact Mass | 377.125458 |
|---|
| PSA | 88.61000 |
|---|
| LogP | 0.46 |
|---|
| Vapour Pressure | 0.0±1.9 mmHg at 25°C |
|---|
| Index of Refraction | 1.652 |
|---|
| InChIKey | YEVOZZZLKJKCCD-UHFFFAOYSA-N |
|---|
| SMILES | CNc1nc(Nc2ccc(C(=O)N3CCOCC3)cc2OC)ncc1Cl |
|---|
| Storage condition | 2-8℃ |
|---|
Synonyms
| [4-[[5-Chloro-4-(methylamino)-2-pyrimidinyl]amino]-3-methoxyphenyl]-4-morpholinylmethanone |
| (4-{[5-Chloro-4-(methylamino)-2-pyrimidinyl]amino}-3-methoxyphenyl)(4-morpholinyl)methanone |
| HG-10-102-01 |
| Methanone, [4-[[5-chloro-4-(methylamino)-2-pyrimidinyl]amino]-3-methoxyphenyl]-4-morpholinyl- |
